SIXTY-SEVENTH WORLD HEALTH ASSEMBLY Provisional agenda item 12.3 A67[removed]March 2014

First Page		Document Content
Date: 2014-03-28 10:49:06 Hepatitis Hepatology Viral diseases Viruses Viral hepatitis Hepatocellular carcinoma Infection Interferon AIDS Medicine Health Biology		SIXTY-SEVENTH WORLD HEALTH ASSEMBLY Provisional agenda item 12.3 A67[removed]March 2014 Add to Reading List Source URL: apps.who.int Download Document from Source Website File Size: 178,02 KB Share Document on Facebook

	PRESS RELEASE AbbVie Receives Health Canada Approval of HOLKIRATM PAK for the Treatment of Chronic Genotype 1 Hepatitis C  New all-oral, short-course (12 weeks), interferon-free treatment available in Canada for geno DocID: 1vlwz - View Document
	IMPORTANT PLEASE READ PART III: CONSUMER INFORMATION INTRON A® interferon alfa-2b This leaflet is part III of a three-part "Product Monograph" DocID: 1uNBi - View Document
	Evaluation of Interferon-gamma-Producing T Cells DocID: 1uFKZ - View Document
	PRODUCT MONOGRAPH INTRON A® interferon alfa-2b Lyophilized Powder with Diluent: 10 million IU interferon alfa-2b/vial DocID: 1umTG - View Document
	  Data Sheet Recombinant Human Interferon-gamma (rh IFN-) Preclinical Grade - Order No.: µg) DocID: 1u1rK - View Document